Antibody Information

General Information of This Antibody
Antibody ID
ANI0IYDRE
Antibody Name
Tusamitamab
Organization
Sanofi-Aventis U.S. LLC
Indication
Solid tumors
Synonyms
SAR408377
   Click to Show/Hide
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Chimeric IgG1-kappa
Antigen Name
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
  Antigen Info 
ChEMBI ID
CHEMBL5095460
Click to Show/Hide the Sequence Information of This Antibody
Heavy Chain Sequence
EVQLQESGPGLVKPGGSLSLSCAASGFVFSSYDMSWVRQTPERGLEWVAYISSGGGITYA
PSTVKGRFTVSRDNAKNTLYLQMNSLTSEDTAVYYCAAHYFGSSGPFAYWGQGTLVTVSS
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN
STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE
LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPG
    Click to Show/Hide
Heavy Chain Varible Domain
EVQLQESGPGLVKPGGSLSLSCAASGFVFSSYDMSWVRQTPERGLEWVAYISSGGGITYA
PSTVKGRFTVSRDNAKNTLYLQMNSLTSEDTAVYYCAAHYFGSSGPFAYWGQGTLVTVSS
    Click to Show/Hide
Heavy Chain Constant Domain 1
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV
    Click to Show/Hide
Heavy Chain Constant Domain 2
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS
    Click to Show/Hide
Heavy Chain Constant Domain 3
GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
    Click to Show/Hide
Heavy Chain Hinge Region
EPKSCDKTHTCPPCPHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKALPAPIEKTISKAK
    Click to Show/Hide
Heavy Chain CDR 1
GFVFSSYD
    Click to Show/Hide
Heavy Chain CDR 2
ISSGGGIT
    Click to Show/Hide
Heavy Chain CDR 3
AAHYFGSSGPFAY
    Click to Show/Hide
Light Chain Sequence
DIQMTQSPASLSASVGDRVTITCRASENIFSYLAWYQQKPGKSPKLLVYNTRTLAEGVPS
RFSGSGSGTDFSLTISSLQPEDFATYYCQHHYGTPFTFGSGTKLEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Light Chain Varible Domain
DIQMTQSPASLSASVGDRVTITCRASENIFSYLAWYQQKPGKSPKLLVYNTRTLAEGVPS
RFSGSGSGTDFSLTISSLQPEDFATYYCQHHYGTPFTFGSGTKLEIK
    Click to Show/Hide
Light Chain Constant Domain
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Light Chain CDR 1
ENIFSY
    Click to Show/Hide
Light Chain CDR 2
NTR
    Click to Show/Hide
Light Chain CDR 3
QHHYGTPFT
    Click to Show/Hide
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Tusamitamab ravtansine [Phase 3]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 9 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Objective Response Rate (ORR)
40.00%
Low CEACAM5 expression (CEACAM5+; 299,300 sites/cell)
Patients Enrolled
Patients with advanced/metastatic nonsquamous non-small cell lung cancer (NSQ NSCLC) with CEACAM5 intensity of 2+ in 1% of tumor cells by immunohistochemistry.
Administration Dosage
IV Q3W at 150 or 170 mg/m2.
Related Clinical Trial
NCT Number NCT04524689  Clinical Status Phase 2
Clinical Description
Open-label, phase 2 study of tusamitamab ravtansine (SAR408701) combined with pembrolizumab and tusamitamab ravtansine (SAR408701) combined with pembrolizumab and platinum-based chemotherapy with or without pemetrexed in patients with CEACAM5 positive expression advanced/metastatic non-squamous non-small-cell lung cancer (nsq NSCLC).
Experiment 2 Reporting the Activity Date of This ADC [2]
Efficacy Data Objective Response Rate (ORR)
20.30% (CEACAM5 High-expression)
7.10% (CEACAM5 Moderate-expression)
41.70% (high cCEA)
8.10% (Low cCEA)
Moderate CEACAM5 expression (CEACAM5++; 1,615,700 sites/cell)
Patients Enrolled
Enrolled 2 cohorts of patients with IHC CEACAM5 membrane expression at 2+ intensity: in 50% of tumor cells (high expressors, HEs, n = 64); and in 1% to <50% of tumor cells (moderate expressors, MEs, n = 28).
Administration Dosage
100 mg/m2 IV every 2 weeks.
Related Clinical Trial
NCT Number NCT02187848  Clinical Status Phase 1
Clinical Description
A first-in-human study for the evaluation of the safety, pharmacokinetics and antitumor activity of SAR408701 in patients with advanced solid tumors.
Primary Endpoint
The primary endpoint was the incidence of DLTs occurring during the first two cycles (4 weeks) of study drug administration. DLTs (reversible grade 3 microcystic keratopathy) occurred in three of eight patients treated with tusamitamab ravtansine 12.00 mg/m2 and in two of three patients treated with 15.00 mg/m2. The maximum tolerated dose was identified as 10.00 mg/m2.

   Click to Show/Hide
Other Endpoint
Three patients (9.68%) had objective responses [all confirmed partial responses (PRs) with durations of 2.60, 6.10, and 4.00 months]; 11 patients (35.48%) had stable disease, and 13 patients (41.94%) had progressive disease. Objective responses were achieved in two of six patients (33.33%) at a DL of 10.0 mg/m2, and in one of nine patients (11.11%) at 12.0 mg/m2 with maximum reduction in RECIST target lesions of 32.30%-51.20%.

   Click to Show/Hide
Experiment 3 Reporting the Activity Date of This ADC [3]
Related Clinical Trial
NCT Number NCT05703555  Clinical Status Phase 2
Clinical Description
Intrusion: unraveling the intratumoral PK/PD relation for SAR408701.
Experiment 4 Reporting the Activity Date of This ADC [4]
Related Clinical Trial
NCT Number NCT05245071  Clinical Status Phase 2
Clinical Description
Open-label, phase 2 study, evaluating the efficacy and safety of tusamitamab ravtansine in non-squamous non-small-cell lung cancer (nsq NSCLC) participants with negative or moderate CEACAM5 expression tumors and high circulating CEA.
Experiment 5 Reporting the Activity Date of This ADC [5]
Related Clinical Trial
NCT Number NCT05071053  Clinical Status Phase 2
Clinical Description
Open-label study of tusamitamab ravtansine (SAR408701) in combination with ramucirumab in participants previously treated for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma with CEACAM5-positive tumors.
Experiment 6 Reporting the Activity Date of This ADC [6]
Related Clinical Trial
NCT Number NCT04659603  Clinical Status Phase 2
Clinical Description
Open-label, multi-cohort, phase 2 trial, evaluating the efficacy and safety of tusamitamab ravtansine (SAR408701) monotherapy and in combination in patients with CEACAM5-positive advanced solid tumors.
Experiment 7 Reporting the Activity Date of This ADC [7]
Related Clinical Trial
NCT Number NCT05429762  Clinical Status Phase 1
Clinical Description
Open-label study evaluating the effect of tusamitamab ravtansine on the QTC interval in participants with metastatic solid tumors.
Experiment 8 Reporting the Activity Date of This ADC [8]
Related Clinical Trial
NCT Number NCT04154956  Clinical Status Phase 1
Clinical Description
Randomized, open-label, phase 3 study of SAR408701 versus docetaxel in previously treated, metastatic nonsquamous, non-small-cell lung cancer patients with CEACAM5-positive tumors.
Experiment 9 Reporting the Activity Date of This ADC [9]
Related Clinical Trial
NCT Number NCT03324113  Clinical Status Phase 1
Clinical Description
A phase 1 study to evaluate safety and pharmacokinetics of SAR408701 administered intravenously as monotherapy in japanese patients with advanced malignant solid tumors.
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 28 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
0.00% (Day 28)
Moderate CEACAM5 expression (CEACAM5++; IHC 2+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a lung adenocarcinoma patient with IHC 2+, with a single intravenous administration at 2.5 mg/kg.
In Vivo Model Lung adenocarcinoma PDX model (PDX: LUN-NIC-014)
Experiment 2 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
6.40% (Day 28)
High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, with a single intravenous administration at 2.5 mg/kg.
In Vivo Model Colon adenocarcinoma PDX model (PDX: CR-IGR-002C/M)
Experiment 3 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
27.10% (Day 28)
High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a stomach adenocarcinoma patient with IHC 3+, with a single intravenous administration at 2.5 mg/kg.
In Vivo Model Stomach adenocarcinoma PDX model (PDX: STO-IND-0007)
Experiment 4 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
32.90% (Day 28)
High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, with a single intravenous administration at 5 mg/kg.
In Vivo Model Colon adenocarcinoma PDX model (PDX: CR-IGR-002C/M)
Experiment 5 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
41.50% (Day 17)
High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a stomach adenocarcinoma patient with IHC 3+, with a single intravenous administration at 2.5 mg/kg.
In Vivo Model Stomach adenocarcinoma PDX model (PDX: SA-STO-0014)
Experiment 6 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
55.00% (Day 28)
High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a stomach adenocarcinoma patient with IHC 3+, twice a week with a single intravenous administration at 2.5 mg/kg for a total of 4 weeks.
In Vivo Model Stomach adenocarcinoma PDX model (PDX: STO-IND-0007)
Experiment 7 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
57.20% (Day 17)
High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a stomach adenocarcinoma patient with IHC 3+, with a single intravenous administration at 5 mg/kg.
In Vivo Model Stomach adenocarcinoma PDX model (PDX: SA-STO-0014)
Experiment 8 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
60.30% (Day 28)
Moderate CEACAM5 expression (CEACAM5++; IHC 2+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a lung adenocarcinoma patient with IHC 2+, with a single intravenous administration at 2.5 mg/kg.
In Vivo Model Lung adenocarcinoma PDX model (PDX: LUN-NIC-0083)
Experiment 9 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
63.90% (Day 28)
High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, with a single intravenous administration at 2.5 mg/kg.
In Vivo Model Colon adenocarcinoma PDX model (PDX: CR-IGR-0034P)
Experiment 10 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
66.20% (Day 28)
Moderate CEACAM5 expression (CEACAM5++; IHC 2+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a lung adenocarcinoma patient with IHC 2+, with a single intravenous administration at 5 mg/kg.
In Vivo Model Lung adenocarcinoma PDX model (PDX: LUN-NIC-0083)
Experiment 11 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
69.70% (Day 28)
High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a stomach adenocarcinoma patient with IHC 3+, with a single intravenous administration at 5 mg/kg.
In Vivo Model Stomach adenocarcinoma PDX model (PDX: STO-IND-0007)
Experiment 12 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
69.80% (Day 28)
Moderate CEACAM5 expression (CEACAM5++; IHC 2+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a lung adenocarcinoma patient with IHC 2+, with a single intravenous administration at 10 mg/kg.
In Vivo Model Lung adenocarcinoma PDX model (PDX: LUN-NIC-0083)
Experiment 13 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
70.20% (Day 28)
High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a stomach adenocarcinoma patient with IHC 3+, with a single intravenous administration at 5 mg/kg.
In Vivo Model Stomach adenocarcinoma PDX model (PDX: STO-IND-0007)
Experiment 14 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
71.80% (Day 28)
Moderate CEACAM5 expression (CEACAM5++; IHC 2+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a lung adenocarcinoma patient with IHC 2+, with a single intravenous administration at 5 mg/kg.
In Vivo Model Lung adenocarcinoma PDX model (PDX: LUN-NIC-014)
Experiment 15 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
76.50% (Day 28)
High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a stomach adenocarcinoma patient with IHC 3+, once a week with a single intravenous administration at 5 mg/kg for a total of 4 weeks.
In Vivo Model Stomach adenocarcinoma PDX model (PDX: STO-IND-0007)
Experiment 16 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
84.70% (Day 28)
High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, with a single intravenous administration at 5 mg/kg.
In Vivo Model Colon adenocarcinoma PDX model (PDX: CR-IGR-0034P)
Experiment 17 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
90.20% (Day 28)
Moderate CEACAM5 expression (CEACAM5++; IHC 2+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a lung adenocarcinoma patient with IHC 2+, with a single intravenous administration at 10 mg/kg.
In Vivo Model Lung adenocarcinoma PDX model (PDX: LUN-NIC-014)
Experiment 18 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
90.30% (Day 28)
Moderate CEACAM5 expression (CEACAM5++; IHC 2+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a lung adenocarcinoma patient with IHC 2+, twice a week with a single intravenous administration at 2.5 mg/kg for a total of 4 weeks.
In Vivo Model Lung adenocarcinoma PDX model (PDX: LUN-NIC-014)
Experiment 19 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
91.40% (Day 28)
High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, with a single intravenous administration at 10 mg/kg.
In Vivo Model Colon adenocarcinoma PDX model (PDX: CR-IGR-002C/M)
Experiment 20 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
92.40% (Day 28)
High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a stomach adenocarcinoma patient with IHC 3+, with a single intravenous administration at 10 mg/kg.
In Vivo Model Stomach adenocarcinoma PDX model (PDX: STO-IND-0007)
Experiment 21 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
92.80% (Day 28)
High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, with a single intravenous administration at 10 mg/kg.
In Vivo Model Colon adenocarcinoma PDX model (PDX: CR-IGR-0034P)
Experiment 22 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
92.80% (Day 28)
High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, with a single intravenous administration at 5 mg/kg.
In Vivo Model Colon adenocarcinoma PDX model (PDX: CR-IGR-0034P)
Experiment 23 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
93.30% (Day 17)
High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a stomach adenocarcinoma patient with IHC 3+, with a single intravenous administration at 10 mg/kg.
In Vivo Model Stomach adenocarcinoma PDX model (PDX: SA-STO-0014)
Experiment 24 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
93.50% (Day 28)
High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, with a single intravenous administration at 5 mg/kg.
In Vivo Model Colon adenocarcinoma PDX model (PDX: CR-IGR-002C/M)
Experiment 25 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
97.00% (Day 28)
High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, once a week with a single intravenous administration at 5 mg/kg for a total of 4 weeks.
In Vivo Model Colon adenocarcinoma PDX model (PDX: CR-IGR-0034P)
Experiment 26 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
99.40% (Day 28)
High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, once a week with a single intravenous administration at 5 mg/kg for a total of 4 weeks.
In Vivo Model Colon adenocarcinoma PDX model (PDX: CR-IGR-002C/M)
Experiment 27 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
99.90% (Day 28)
High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, twice a week with a single intravenous administration at 2.5 mg/kg for a total of 4 weeks.
In Vivo Model Colon adenocarcinoma PDX model (PDX: CR-IGR-002C/M)
Experiment 28 Reporting the Activity Date of This ADC [10]
Efficacy Data Tumor Growth Inhibition value (TGI)
100.00% (Day 28)
High CEACAM5 expression (CEACAM5+++; IHC 3+)
Method Description
Tusamitamab ravtansine induces efficient tumor cell killing in PDX models of a colon adenocarcinoma patient with IHC 3+, twice a week with a single intravenous administration at 2.5 mg/kg for a total of 4 weeks.
In Vivo Model Colon adenocarcinoma PDX model (PDX: CR-IGR-0034P)
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [10]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.20±0.04 nM
Low CEACAM5 expression (CEACAM5+; 498,900 sites/cell)
Method Description
The inhibitory activity of SAR408377 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated incubated overnight.
In Vitro Model Pancreatic ductal adenocarcinoma HPAF-II cells CVCL_0313
Experiment 2 Reporting the Activity Date of This ADC [10]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.38±0.07 nM
Method Description
The inhibitory activity of SAR408377 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated incubated overnight.
In Vitro Model Pancreatic ductal adenocarcinoma HPAF-II cells CVCL_0313
Experiment 3 Reporting the Activity Date of This ADC [10]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.08±0.17 nM
Method Description
The inhibitory activity of SAR408377 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated incubated overnight.
In Vitro Model Gastric adenocarcinoma MKN45 cells CVCL_0434
References
Ref 1 Preliminary results from a first-in-human study of ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors. J Clin Oncol. 2023 41:16_suppl, 1100-1100.
Ref 2 Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022 Apr;33(4):416-425.
Ref 3 INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701, NCT05703555
Ref 4 Open-label, Phase 2 Study, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine in Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA, NCT05245071
Ref 5 Open-label Study of Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Participants Previously Treated for Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma With CEACAM5-positive Tumors, NCT05071053
Ref 6 Open-label, Multi-cohort, Phase 2 Trial, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine (SAR408701) Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors, NCT04659603
Ref 7 Open-label Study Evaluating the Effect of Tusamitamab Ravtansine on the QTc Interval in Participants With Metastatic Solid Tumors, NCT05429762
Ref 8 Randomized, Open-label, Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated, Metastatic Nonsquamous, Non-small-cell Lung Cancer Patients With CEACAM5-positive Tumors, NCT04154956
Ref 9 A Phase I Study to Evaluate Safety and Pharmacokinetics of SAR408701 Administered Intravenously as Monotherapy in Japanese Patients With Advanced Malignant Solid Tumors, NCT03324113
Ref 10 Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors. Clin Cancer Res. 2020 Dec 15;26(24):6589-6599.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.